Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D7GYE9
|
|||
| Drug Name |
SB15
|
|||
| Synonyms |
Aflibercept Biosimilar
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Neovascular age-related macular degeneration [ICD-11: 9B78.3Z; ICD-9: 362.5] | Phase 3 | [1] | |
| Company |
Biogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor (VEGF) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04450329) A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB15 (Proposed Aflibercept Biosimilar) and Eylea? in Subjects With Neovascular Age-related Macular Degeneration. U.S.National Institutes of Health. | |||
| REF 2 | Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.